Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
MARKSANS
Mr. Mark B. Saldanha · Mumbai, India
₹259.45
▲+1.09%Marksans Pharma is delivering solid top‑line growth and improving margins while trading near the upper end of its 52‑week range, driven by strong domestic formulation sales and export momentum.
Exchange
NSI
Currency
INR
Day range
₹256.85 – ₹264.15
52-week range
₹155.00 – ₹281.60
Sector
Healthcare
Industry
Drug Manufacturers - General
AI investment rating
AI analysis78% confidence
At ~₹259 the stock sits in the upper third of its yearly range and trades at a P/E modestly above the sector average, suggesting fair value is close to current levels with limited upside unless earnings accelerate.
7.9% below the 1-year high · trend down
Hedge-fund memo
Today
Price up ~1% on modest volume, trading near the day‑high.
This week
Over the past week the share has risen roughly 3‑4% as investors reacted to healthy quarterly results.
This month
Month‑to‑date the stock is up about 8‑10%, outperforming the Nifty Pharma index.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
3 headlines · 2 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 2 recent quarters (EPS actual vs. consensus).
3.27 vs 3.3
-0.91% surprise
2.5 vs 2.4
4.17% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| MARKSANS | 117.57B | 28.17 | 15.16% | 19.99% | 20.80% |
| MOREPENLAB | 31.70B | 33.44 | 7.86% | 3.86% | 4.00% |
| GRANULES | 208.61B | 31.21 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory pricing pressure in US/EU markets
Mitigation: Diversify into emerging markets and increase contract manufacturing
Dependence on limited product portfolio
Mitigation: Accelerate ANDA filings and launch new generics
Business intelligence
Competitive moat
Marksans enjoys a cost‑effective manufacturing base and a growing portfolio of niche generics that provide pricing power in regulated markets.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Earnings announcement
Potential US FDA approval for a new generic
Thesis builder
Bull case
Strong revenue growth, improving margins, and a clean balance sheet support rerating to higher multiples.
Base case
Steady mid‑single‑digit earnings growth continues, keeping the stock roughly fair valued.
Bear case
Growth slows or margin pressure emerges, pulling the P/E toward sector average and pressuring the share price.
Time horizon
12‑18 months
Est. CAGR
approx range: 12‑18% EPS CAGR
Entry (qual.)
Look to enter on pullbacks to the ₹230‑250 band
Exit (qual.)
Consider exiting if price breaks above ₹300 on sustained multiple expansion or falls below ₹200 on an earnings miss.
Overall conviction 78%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how MARKSANS fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain MARKSANS for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Consider accumulating on dips below ₹250 with a medium‑term outlook, while keeping a stop‑loss near the 52‑week low.
CNBC TV18·5d ago·direct plan announcement
MarketsMojo·6d ago·strong earnings upgrade
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| — |
| 17.56% |
| 22.00% |
| SUVEN | 88.54B | — | -78.80% | -3,435.00% | 3.60% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹256.85
Resistance (day/52w high)
₹264.15
Volume
7,05,404
Trend
down
RSI (14)
39
MACD
bearish
MA cross
golden
50-day MA
₹253.55
200-day MA
₹198.76
vs 200-DMA
30.5%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.